STAT3 and prostate cancer: By chromatin immunoprecipitation, STAT3 has been shown to play a role in LDLR transcription in prostate cancer, where treatment with 27-hydroxycholesterol resulted in reduced binding of STAT3 to the LDLR promoter, concurrent with a reduction in LDLR expression22.